Gui, G., Ravindra, N., Hegde, P. S., Andrew, G., Mukherjee, D., Wong, Z., Auletta, J. J., El Chaer, F., Chen, E. C., Chen, Y.-B., Corner, A., Devine, S. M., Iyer, S. G., Jimenez Jimenez, A. M., De Lima, M. J. G., Litzow, M. R., Kebriaei, P., Saber, W., Spellman, S. R., … Hourigan, C. S. (2024). Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-024-02449-2

Shah, N. N., Wang, M., Roeker, L. E., Patel, K., Woyach, J. A., Wierda, W. G., Ujjani, C. S., Eyre, T. A., Inzani, P. L. Z., Alencar, A. J., Ghia, P., Lamanna, N., Hoffmann, M. S., Patel, M. R., Flinn, I., Gerson, J. N., Ma, S., Coombs, C. C., Cheah, C. Y., … Brown, J. R. (2024). Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. Haematologica. https://doi.org/10.3324/haematol.2024.285754

Patel, A. A., Yoon, J. J., Johnston, H., Davidson, M. B., Shallis, R. M., Chen, E. C., Burkart, M., Oh, T. S., Iyer, S. G., Madarang, E., Muthiah, C., Gross, I., Dean, R., Kassner, J., Viswabandya, A., Madero-Marroquin, R., Rampal, R. K., Guru Murthy, G. S., Bradley, T., … Odenike, O. (2024). Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era. Blood Advances, 8(13), 3468–3477. https://doi.org/10.1182/bloodadvances.2024012880

Brivio, E., Pennesi, E., Willemse, M. E., Huitema, A. D. R., Jiang, Y., van Tinteren, H. D. R., van der Velden, V. H. J., Beverloo, B. H., den Boer, M. L., Rammeloo, L. A. J., Hudson, C., Heerema, N., Kowalski, K., Zhao, H., Kuttschreuter, L., Bautista Sirvent, F. J., Bukowinski, A., Rizzari, C., Pollard, J., … Zwaan, C. M. (2024). Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921. Journal of Clinical Oncology, 42(7), 821–831. https://doi.org/10.1200/jco.23.00897

Brown, J. R., Ghia, P., Jurczak, W., Kahl, B. S., Lamanna, N., Robak, T., Shadman, M., Tam, C. S., Qiu, L., Paik, J., Salmi, T., Wang, L., Zhang, J., Zhang, M., Cohen, A., Ma, H., & Tedeschi, A. (2024). Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database. Haematologica. https://doi.org/10.3324/haematol.2023.283846

Lee, M. H., Song, A., & Li, J. Y. (2024). Erythroid variant evolving from chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitors: a rare case report. Diagnostic Pathology, 19(1). https://doi.org/10.1186/s13000-024-01446-9

Hijiya, N., Maschan, A., Rizzari, C., Shimada, H., Dufour, C., Goto, H., Kang, H. J., Guinipero, T., Karakas, Z., Bautista, F., Ducassou, S., Yoo, K. H., Zwaan, C. M., Millot, F., Patterson, B. C., Samis, J., Izquierdo, M., Titorenko, K., Li, S., & Sosothikul, D. (2023). The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study. Blood Advances, 7(23), 7279–7289. https://doi.org/10.1182/bloodadvances.2023010122

Chakraborty, R., Bhutani, D., Mapara, M., Reshef, R., Maurer, M. S., Radhakrishnan, J., & Lentzsch, S. (2023). Reduced Early Mortality with Daratumumab-Based Frontline Therapy in Systemic AL Amyloidosis- Experience from the Columbia Amyloidosis Multidisciplinary Program. Blood, 142(Supplement 1), 4780–4780. https://doi.org/10.1182/blood-2023-187214

Wang, E. S., Jonas, B. A., Watts, J. M., Jurcic, J., Ferrell, P. B., Dinner, S. N., Yang, J., Seiter, K., Mims, A., Donnellan, W. B., Blum, W., & Cortes, J. (2023). Factors Impacting Response to Olutasidenib in Patients with mIDH1 Acute Myeloid Leukemia. Blood, 142(Supplement 1), 6047–6047. https://doi.org/10.1182/blood-2023-187584

Cortes, J., Jurcic, J., Baer, M. R., Blum, W., Ferrell, P. B., Jonas, B. A., Lee, S., Mims, A., Patel, S. A., Schiller, G. J., Yang, J., & Watts, J. M. (2023). Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax. Blood, 142(Supplement 1), 2888–2888. https://doi.org/10.1182/blood-2023-187861

Chernak, B., Galan-Diez, M., Ali, A. M., Cuesta-Dominguez, A., Chen, Z., Koehnke, T., Majeti, R., Carroll, M., Raza, A., & Kousteni, S. (2023). Serum Amyloid A1 (SAA1) Secreted By the Stromal Microenvironment Drives Malignant Clonal Proliferation in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood, 142(Supplement 1), 4118–4118. https://doi.org/10.1182/blood-2023-174485

Hijiya, N., Kapoor, S., Hoch, M., Descamps, L., Dhamal, V., & Torres Cardoso, A. P. (2023). ASC4KIDS: A Multicenter, Open-Label, Phase Ib/II Study to Determine the Dose and Safety of Asciminib in Pediatric Patients with Chronic Myeloid Leukemia in the Chronic Phase. Blood, 142(Supplement 1), 6387–6387. https://doi.org/10.1182/blood-2023-185535

Lipsky, A. H., Hill, B. T., Winter, A., Bachow, S. H., Viny, A. D., Rosenblat, T. L., Jurcic, J., & Lamanna, N. (2023). Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL): High Rates of Undetectable Minimal Residual Disease Remissions. Blood, 142(Supplement 1), 3274–3274. https://doi.org/10.1182/blood-2023-189718

Patel, A. A., Yoon, J. J., Johnston, H., Davidson, M. B., Viswabandya, A., Shallis, R. M., Chen, E. C., Burkart, M., Oh, T. S., Iyer, S. G., Madarang, E., Muthiah, C., Dean, R., Kassner, J., Rampal, R. K., Guru Murthy, G. S., Bradley, T., Abaza, Y., Garcia, J. S., … Odenike, O. (2023). Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies. Blood, 142(Supplement 1), 3192–3192. https://doi.org/10.1182/blood-2023-174790

Coombs, C. C., Woyach, J. A., Brown, J. R., Ghia, P., Roeker, L. E., Patel, K., Eyre, T. A., Tam, C. S., Seymour, J. F., Shah, N. N., Flinn, I. W., Cheah, C. Y., Ma, S., Rhodes, J. M., Izutsu, K., Jurczak, W., Wierda, W. G., Loubert, A., Payakachat, N., … Lamanna, N. (2023). Patient-Reported Outcomes (PROs) Among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Pirtobrutinib: Analysis from the BRUIN Phase 1/2 Study. Blood, 142(Supplement 1), 6535–6535. https://doi.org/10.1182/blood-2023-186145

Lamanna, N., Tam, C., Jurczak, W., Kontos, A., Konig, H., Ruppert, A., Tsai, D., & Scheliga, A. (2023). COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS. Hematology, Transfusion and Cell Therapy, 45, S161. https://doi.org/10.1016/j.htct.2023.09.359

Van Tine, B. A., Ingham, M. A., Attia, S., Meyer, C. F., Baird, J. D., D’Silva, D., O’Keefe, K., Kong, R., Maliakal, P., Gao, L., & Schwartz, G. K. (2023). 1934P Pharmacokinetics of unesbulin in a phase Ib study of patients with advanced leiomyosarcoma. Annals of Oncology, 34, S1039. https://doi.org/10.1016/j.annonc.2023.09.1163

VanderVeer, E., Huang, S. J. T., Bruyere, H., Li, C., Ramadan, K., Villa, D., Scott, D. W., Savage, K. J., Connors, J. M., Sehn, L. H., Toze, C. L., & Gerrie, A. S. (2023). POSTER: CLL-617 Long Term Outcomes and Secondary Malignancies in 673 Patients Treated With Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL) in British Columbia (BC), CanadaElys. Clinical Lymphoma Myeloma and Leukemia, 23, S173. https://doi.org/10.1016/s2152-2650(23)00531-1

Hijiya, N., Heneghan, M., Kapoor, S., Dhamal, V., Hoch, M., Descamps, L., Cardoso, A. P., & Pollard, J. (2023). POSTER: CML-532 ASC4KIDS: A Multicenter, Open-Label, Phase 1b/2 Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Clinical Lymphoma Myeloma and Leukemia, 23, S180. https://doi.org/10.1016/s2152-2650(23)00574-8

Schlenk, R. F., Montesinos, P., Romero-Aguilar, A., Vrhovac, R., Patkowska, E., Kim, H.-J., Zak, P., Wang, P.-N., Hanyok, J., Liu, L., Kamel, Y. M., Lesegretain, A., Cortes, J., Sekeres, M. A., Dombret, H., Amadori, S., Wang, J., Perl, A. E., Levis, M. J., & Erba, H. P. (2023). POSTER: CT-186 Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition With Quizartinib in Acute Myeloid Leukemia (AML) With FLT3–Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial. Clinical Lymphoma Myeloma and Leukemia, 23, S229. https://doi.org/10.1016/s2152-2650(23)00885-6

Konig, H., Tam, C. S., Lamanna, N., Jurczak, W., Kontos, A., Ruppert, A. S., & Tsai, D. E. (2023). POSTER: CT-168 Comparison of Bleeding-Related Events in Patients Who Received Pirtobrutinib With and Without Antithrombotic Agents. Clinical Lymphoma Myeloma and Leukemia, 23, S229. https://doi.org/10.1016/s2152-2650(23)00884-4

Niehus, H., Sabile, J., Maziarz, R. T., Meyers, G., Cook, R., Gandhi, A., Saultz, J. N., Rakshe, S., Kaempf, A., Braun, T., & Migdady, Y. (2023). POSTER: MDS-009 Enhanced Survival of Chronic Myelomonocytic Leukemia (CMML)-Dysplastic Over the Proliferative Subtype After Allogeneic Hematopoietic Cell Transplantation: A Tertiary Center Experience. Clinical Lymphoma Myeloma and Leukemia, 23, S180. https://doi.org/10.1016/s2152-2650(23)00576-1

Brown, J. R., Eichhorst, B., Ghia, P., Jurczak, W., Kahl, B., Lamanna, N., Robak, T., Shadman, M., Tam, C., Qiu, L., Cohen, A., Zhang, M., Salmi, T., Paik, J., Wang, L., Zhang, J., MA, H., & Tedeschi, A. (2023). P631: CHARACTERIZATION OF ZANUBRUTINIB SAFETY/TOLERABILITY PROFILE AND COMPARISON WITH IBRUTINIB PROFILE IN PATIENTS WITH B-CELL MALIGNANCIES: POST HOC ANALYSIS OF A LARGE CLINICAL TRIAL SAFETY DATABASE. HemaSphere, 7(S3), e356884b. https://doi.org/10.1097/01.hs9.0000969428.35688.4b

Lamanna, N., Tam, C., Jurczak, W., Kontos, A., Konig, H., Ruppert, A. S., & Tsai, D. E. (2023). P1088: COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS. HemaSphere, 7(S3), e724362f. https://doi.org/10.1097/01.hs9.0000971248.72436.2f

Hijiya, N., Kapoor, S., Hoch, M., Descamps, L., Dasgupta, K., & Cardoso, A. P. T. (2023). PB1980: ASC4KIDS: A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO DETERMINE THE DOSE AND SAFETY OF ASCIMINIB IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE. HemaSphere, 7(S3), e1669755. https://doi.org/10.1097/01.hs9.0000974736.16697.55

Brivio, E., Pennesi, E., Willemse, M., Jiang, Y., van der Velden, V., Beverloo, B., Hudson, C., Kuttschreuter, L., van der Sluis, I., Brethon, B., Bautista, F., J. Burke, M., Heerema, N., Bukowinski, A., Cooper, S., Pollard, J., Nagasubramani, R., Redell, M., Bourquin, J.-P., … Zwaan, M. (2023). P676: UPDATED RESULTS FROM THE TRIAL ITCC-054/COG-AAML1921: BOSUTINIB IN NEWLY DIAGNOSED AND RESISTANT/INTOLERANT PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA. HemaSphere, 7(S3), e506783a. https://doi.org/10.1097/01.hs9.0000969608.50678.3a

Shadman, M., Manzoor, B. S., Sail, K., Tuncer, H. H., Allan, J. N., Ujjani, C., Emechebe, N., Kamalakar, R., Coombs, C. C., Leslie, L., Barr, P. M., Brown, J. R., Eyre, T. A., Rampotas, A., Schuh, A., Lamanna, N., Skarbnik, A., Roeker, L. E., Bannerji, R., … Mato, A. R. (2023). Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study. Clinical Lymphoma Myeloma and Leukemia, 23(7), 515–526. https://doi.org/10.1016/j.clml.2023.03.010

Oberlin, A., Krenitsky, N. M., Gandhi, C., Akpan, I. J., Eisenberger, A., Landau, R., Yurteri-Kaplan, L., Nathan, L., Sheen, J.-J., LaSala, A., & D’Alton, M. (2023). Acquired Hemophilia A: A Rare, Acquired Coagulopathy in the Postpartum Setting. American Journal of Perinatology Reports, 13(04), e85–e88. CLOCKSS. https://doi.org/10.1055/a-2198-7888

Jurczak, W., Lamanna, N., Tam, C. S., Kontos, A., Konig, H., Ruppert, A. S., & Tsai, D. E. (2023). COMPARISON OF BLEEDING‐RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS. Hematological Oncology, 41(S2), 758–759. Portico. https://doi.org/10.1002/hon.3165_605

Brown, J. R., Eichorst, B., Ghia, P., Jurczak, W., Kahl, B. S., Lamanna, N., Robak, T., Shadman, M., Tam, C. S., Qiu, L., Cohen, A., Zhang, M., Salmi, T., Paik, J., Wang, L., Zhang, J., Ma, H., & Tedeschi, A. (2023). Zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in B‐cell malignancies: Post hoc analysis of a large clinical trial safety database. Hematological Oncology, 41(S2), 459–461. Portico. https://doi.org/10.1002/hon.3164_339

Lee, H., Choi, M., Siddiqi, T., Rhodes, J., Wierda, W., Isufi, I., Tuscano, J., Lamanna, N., Subbiah, S., Koff, J., Leslie, L., Goldenberg, A., Chung, G., Breitmeyer, J., Yazji, S., Shih, T., Wang, M., Jamieson, C., & Kipps, T. (2023). Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL). Hematological Oncology, 41(S2), 587–589. Portico. https://doi.org/10.1002/hon.3164_440

Sallman, D. A., Al Malki, M. M., Asch, A. S., Wang, E. S., Jurcic, J. G., Bradley, T. J., Flinn, I. W., Pollyea, D. A., Kambhampati, S., Tanaka, T. N., Zeidner, J. F., Garcia-Manero, G., Jeyakumar, D., Komrokji, R., Lancet, J., Kantarjian, H. M., Gu, L., Zhang, Y., Tan, A., … Daver, N. G. (2023). Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. Journal of Clinical Oncology, 41(15), 2815–2826. https://doi.org/10.1200/jco.22.01794

Hijiya, N., Kapoor, S., Hoch, M., Descamps, L., Dasgupta, K., & Ramscar, N. (2022). ASC4KIDS: A Multicenter, Open-Label, Phase Ib/II Study to Determine the Dose and Safety of Asciminib in Pediatric Patients with Chronic Myeloid Leukemia in Chronic Phase. Blood, 140(Supplement 1), 12204–12205. https://doi.org/10.1182/blood-2022-162451

Granat, L. M., Li, H., Anwer, F., Sheu, M., Faiman, B. M., Khouri, J., Mazzoni, S., Valent, J., Samaras, C. J., Chakraborty, R., Chaulagain, C. P., van Heeckeren, W. J., & Williams, L. S. (2022). Hypercalcemia: A Risk Factor for Early Disease Progression and Poor Survival in Cytogenetically Standard-Risk Multiple Myeloma. Blood, 140(Supplement 1), 4290–4291. https://doi.org/10.1182/blood-2022-168040

Stiefel, J., Flower, A. M., Botwinick, M., Ford, M., Foti, A., Gandhi, M., Slovin, J., Smilow, E., Bowers, A., Karpel, H., Schwartz, L. Y., Fraint, E., Gennarini, L. M., Gardner, S. L., Raetz, E. A., Shah, N. C., Chen, J., Krajewski, J., Hijiya, N., … Sulis, M. L. (2022). Antigen Directed Therapy Pre-Transplant Confers Superior Post-Transplant Survival Outcome Compared to Conventional Chemotherapy in Pediatric Patients with Relapsed and Refractory B-ALL. Blood, 140(Supplement 1), 7763–7765. https://doi.org/10.1182/blood-2022-160272

Hijiya, N., Kapoor, S., Hoch, M., Descamps, L., Bayar, M. A., & Ramscar, N. (2022). PB1903: TRIAL IN PROGRESS: A MULTICENTER, OPEN-LABEL, PHASE IB/II STUDY TO DETERMINE THE DOSE AND SAFETY OF ASCIMINIB IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP). HemaSphere, 6, 1782–1783. https://doi.org/10.1097/01.hs9.0000850464.45271.b3

Youn, M., Smith, S. M., Lee, A. G., Chae, H.-D., Spiteri, E., Erdmann, J., Galperin, I., Jones, L. M., Donato, M., Abidi, P., Bittencourt, H., Lacayo, N., Dahl, G., Aftandilian, C., Davis, K. L., Matthews, J. A., Kornblau, S. M., Huang, M., Sumarsono, N., … Sakamoto, K. M. (2021). Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. Cancers, 13(24), 6263. https://doi.org/10.3390/cancers13246263